PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference
2024年5月17日 - 10:35PM
PsychedelicNewsWire (“PNW”), a specialized communications
platform for the psychedelics sector and one of the 60+ brands
powered by IBN (“InvestorBrandNetwork”), is pleased to announce
that it will be the Official Media Sponsor for the 4th Annual
Psychedelic Therapeutics and Drug Development Conference (“the
conference”), an industry flagship event dedicated to research and
development of psychedelics in the healthcare space hosted by
Arrowhead SciTech Conferences & Events (“Arrowhead”). The event
will be held at the iconic Revere Hotel Boston Common, 200 Stuart
Street, Boston, MA 02116 on 23-24 May 2024.
The two-day conference attracts and features the world’s leading
researchers and thought leaders in academia, industry, the
non-profit sector, and government that aim to bridge gaps in the
R&D sphere related to therapeutic psychedelics for a variety of
health conditions and unmet needs, including
inflammatory/autoimmune disorders, brain injury, pain, PTSD,
anxiety, ADHD, headaches, depression, and opioid use disorder.
IBN and PNW will leverage sophisticated state-of-the-art
communications tools to optimize dedicated virtual coverage for the
event, including amplified article syndication disseminated
throughout IBN’s 5,000+ strategic distribution partners. In
addition, IBN will publish featured placements of the conference on
its Events page and will share social media coverage through its
online accounts which have garnered 2+ million likes, followers,
and subscribers across a variety of platforms and associated
brands.
John Waslif, Managing Director, at Arrowhead, said, “With the
series entering its fourth year, we are pleased to have
PsychedelicNewsNetwork acting as our media partner for our May 2024
event. Having built a strong reputation for research and
development events in the psychedelic-drug development-healthcare
space, we believe that InvestorBrandNetwork and its affiliates are
the ideal partners to drive recognition for our speakers,
participating organizations, and the conference itself. IBN’s
world-class communications outreach and services will play a key
role in elevating the visibility of the event and driving home the
importance of such collaborative efforts across target audiences.
We look forward to working with their highly professional and
energetic team.”
Randy Clark Director of Global Operations at IBN,
added "The Annual Psychedelic Therapeutics and Drug Development
Conference has proved to be an invaluable resource for
academicians, industry experts, and businesspeople in the
fast-evolving psychedelics ecosystem. This event series has
garnered a strong reputation for creating and enabling
opportunities for cutting-edge educational experiences, avenues for
collaborative research, and high-powered networking. We are
thrilled to continue our association and look forward to deploying
state-of-the-art social media tools and communications strategies
to elevate the visibility of the conference while contributing to
the discourse on psychedelics, drug development, and healthcare.
The Boston conference is a must-attend event for anyone interested
in the psychedelics and drug development sectors.”
For more information on the event, visit,
https://psychedelics-conference.com/
About IBN
IBN is a cutting-edge corporate communications and content
distribution company consisting of over 60+ investor facing brands
introduced to the investment public over the last 18+ years while
amassing a collective audience of millions of social media
followers. These distinctive investor brands aim to fulfil the
unique needs of a growing base of client-partners. IBN will
continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized
teams of experts to serve our increasingly diversified list of
clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides:
(1) access to a network of wire solutions
via InvestorWire to reach all target markets, industries
and demographics in the most effective manner possible; (2) article
and editorial syndication to 5,000+ news outlets;
(3) Press Release Enhancement to ensure maximum impact;
(4) full-scale distribution to a growing social
media audience; (5) a full array of corporate
communications solutions; and (6) total news coverage
solutions.
For more information, please
visit https://www.InvestorBrandNetwork.comPlease see full
terms of use and disclaimers on the InvestorBrandNetwork website
applicable to all content provided by IBN, wherever published or
re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com